What is Oxitec?
Oxitec specializes in developing and deploying advanced biological solutions for insect control, primarily targeting disease-carrying mosquitoes like Aedes aegypti. Their flagship technology involves releasing non-biting male mosquitoes that mate with wild females, producing offspring that do not survive to adulthood, thereby suppressing wild populations. This environmentally friendly approach significantly reduces the need for chemical insecticides and has demonstrated substantial efficacy in field trials, including a notable 95% suppression rate in dengue-prone areas of Brazil. The company's innovation aims to drastically cut costs associated with traditional insect release programs, potentially by up to 90%.
How much funding has Oxitec raised?
Oxitec has raised a total of $35.2M across 5 funding rounds:
Private Equity
$2.6M
Private Equity
$3M
Private Equity
$12.6M
Private Equity
$10.2M
Private Equity
$6.8M
Private Equity (2005): $2.6M with participation from Oxford Capital Partners, East Hill Management Company, LLC, and Oxford University
Private Equity (2007): $3M led by East Hill Management Company, LLC and Oxford Capital Partners
Private Equity (2012): $12.6M supported by Oxford Capital Partners and Asia Pacific Capital
Private Equity (2014): $10.2M featuring East Hill Management, Oxford Capital Partners, and Oxford University
Private Equity (2021): $6.8M backed by The Wellcome Trust
Key Investors in Oxitec
The Wellcome Trust
The Wellcome Trust is a global charitable foundation supporting discovery research and tackling urgent health challenges. Their investment in Oxitec likely aligns with their mission to improve health through scientific advancement.
Oxford Capital Partners
Oxford Capital Partners is an investment manager providing growth capital to smaller companies across various industries. Their involvement suggests a belief in Oxitec's potential for significant business expansion.
East Hill Management Company, LLC
East Hill Management Company focuses on investing in early-stage life sciences and physical sciences companies with strong IP. Their investment in Oxitec highlights the company's innovative scientific foundation and commercialization potential.
What's next for Oxitec?
The recent major strategic investment signals a pivotal stage for Oxitec, likely indicating a Series B or later funding round aimed at scaling operations and expanding global reach. This capital will be instrumental in commercializing their technology further, entering new markets, and potentially developing additional pest control solutions. Oxitec's trajectory suggests a strong focus on sustainable pest management, aligning with increasing global demand for eco-friendly public health interventions. Future developments may include broader application of their technology against other invasive insect species and further refinement of their cost-reduction strategies.
See full Oxitec company page
